Immunogenicity and Safety Study of One Dose of GSK Biologicals Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra in Healthy Subjects Aged 10-25 Years.

Trial Profile

Immunogenicity and Safety Study of One Dose of GSK Biologicals Meningococcal Vaccine GSK 134612 (Blinded Lots) Versus One Dose of Menactra in Healthy Subjects Aged 10-25 Years.

Completed
Phase of Trial: Phase II

Latest Information Update: 12 Jun 2017

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary)
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections; Meningococcal infections
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 01 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 04 Mar 2011 Planned end date changed from 1 Feb 2011 to 1 Mar 2011 as reported by ClinicalTrials.gov.
    • 18 Feb 2011 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top